Generic competition · all medicines · read 12 November 2026

Is there a generic of Upadacitinib, and who makes it?

Upadacitinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.

Upadacitinib2 dosage-form groups in the Orange Book

0generic makers listed

Upadacitinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Extended Release, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Rinvoq. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

26 April 2027Exclusivity I-946 Rinvoq
26 April 2027Exclusivity NPP Rinvoq
28 April 2028Exclusivity I-966 Rinvoq
26 April 2031Exclusivity ODE-481 Rinvoq
28 April 2032Exclusivity ODE-538 Rinvoq
15 January 2031Patent 8962629 drug substance
16 August 2033Patent RE47221 drug substance
17 October 2036Patent 11512092
17 October 2036Patent 11365198
17 October 2036Patent 11773106
17 October 2036Patent 11976077
17 October 2036Patent 11524964
17 October 2036Patent 11795175

37 more patents are listed.

Solution, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Rinvoq Lq. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

26 April 2027Exclusivity NP Rinvoq Lq
26 April 2031Exclusivity ODE-481 Rinvoq Lq
15 January 2031Patent 8962629 drug substance
16 August 2033Patent RE47221 drug substance
17 October 2036Patent 12365689
17 October 2036Patent 9951080 drug substance
17 October 2036Patent 10981923 drug substance
17 October 2036Patent 11680069 drug substance
17 October 2036Patent 12110298 drug substance
17 October 2036Patent 11718627 drug substance

3 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.